What it's for (Indications)
- Lenograstim is indicated for the reduction in the duration of neutropenia and its clinical sequelae (e.
- g.
- , febrile neutropenia) in patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies.
- It is also utilized for the reduction of the duration of neutropenia and its complications following myeloablative therapy followed by bone marrow transplantation.
- Furthermore, lenograstim is indicated for the mobilization of peripheral blood progenitor cells (PBPCs) for autologous or allogeneic transplantation, facilitating hematopoietic reconstitution post-chemotherapy.
- Its therapeutic utility extends to the long-term treatment of patients with severe congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia to significantly increase neutrophil counts and reduce the incidence and duration of infection-related events, thereby improving quality of life and clinical outcomes in these chronic conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of lenograstim is highly individualized based on the specific indication, the patient's body weight, and the concurrent treatment regimen. For chemotherapy-induced neutropenia, the typical recommended dose is 5 micrograms/kg/day (or 150 micrograms/m²/day) administered via subcutaneous injection. In patients undergoing myeloablative therapy followed by bone marrow transplantation, a higher dose of 10 micrograms/kg/day is generally administered. For peripheral blood progenitor cell mobilization, a dose of 10 micrograms/kg/day is typically given, either alone or following chemotherapy. Treatment should be continued until the absolute neutrophil count (ANC) has recovered to acceptable, stable levels, usually after the post-chemotherapy nadir, and must be carefully monitored by serial complete blood counts (CBC) with differential counts to ensure appropriate therapeutic response and to manage potential adverse effects. |
Safety & Warnings
Common Side Effects
- Commonly observed side effects associated with lenograstim therapy include musculoskeletal pain, predominantly bone pain (which can range from mild to severe and is generally manageable with analgesics), headache, and generalized fatigue.
- Other frequently reported adverse events include nausea, vomiting, alopecia, and diarrhea, particularly when lenograstim is administered concurrently with highly emetogenic chemotherapy regimens.
- Local injection site reactions, such as pain, erythema, or swelling, may also occur.
- Less common but notable side effects include mild to moderate leukocytosis, transient thrombocytopenia, and reversible elevations in liver enzymes (e.
- g.
- , ALT, AST) or lactate dehydrogenase.
- Patients should be thoroughly informed about potential side effects and advised to promptly report any new or concerning symptoms to their healthcare provider for appropriate assessment and management strategies.
Serious Warnings
- Black Box Warning: While lenograstim does not carry a formal FDA-mandated Black Box Warning, healthcare professionals and patients must be acutely aware of several severe, potentially life-threatening adverse events that necessitate immediate clinical vigilance and patient education. These critical safety concerns include the potential for **splenic rupture**, which has been reported in patients receiving G-CSF, particularly during peripheral blood progenitor cell mobilization, and can be fatal; patients must be counselled to report any new onset of left upper abdominal or shoulder pain immediately. **Acute Respiratory Distress Syndrome (ARDS)** has occurred in some patients, characterized by rapid onset of fever, dyspnea, and pulmonary infiltrates, requiring prompt medical intervention. **Serious allergic reactions, including anaphylaxis**, can manifest rapidly, necessitating immediate cessation of therapy and emergency medical management. Furthermore, **Capillary Leak Syndrome (CLS)** and **aortitis** have been reported as rare but serious systemic complications that demand close monitoring. These serious risks underscore the critical importance of vigilant patient monitoring throughout the course of lenograstim therapy.
- Patients receiving lenograstim require careful clinical and laboratory monitoring to effectively manage potential adverse effects and ensure therapeutic safety.
- It is essential to monitor white blood cell (WBC) counts regularly; if WBC counts exceed 50 x 10^9/L, particularly during peripheral blood progenitor cell (PBPC) mobilization, lenograstim should be temporarily discontinued or the dose reduced to avoid severe leukocytosis and associated complications.
- Careful monitoring of platelet counts is also crucial, as dose-dependent thrombocytopenia has been observed.
- Lenograstim should be used with extreme caution, if at all, in patients with pre-existing myelodysplastic syndrome (MDS) or chronic myeloid leukemia (CML) due to the theoretical risk of accelerating disease progression or transforming into acute myeloid leukemia (AML); it is explicitly not approved for use in these conditions.
- The G-CSF receptor has been identified on some tumor cells, raising theoretical concerns about its potential to stimulate tumor growth, although the clinical significance of this finding remains unestablished.
- Patients with sickle cell trait or disease should be closely monitored for the exacerbation of sickle cell crisis.
- Long-term use of G-CSF in patients with chronic severe neutropenia may be associated with bone density changes, requiring consideration of osteoporosis screening.
How it Works (Mechanism of Action)
Lenograstim is a glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) that acts as a potent hematopoietic growth factor. Its primary mechanism of action involves binding to specific G-CSF receptors expressed on the surface of hematopoietic stem cells, progenitor cells, and mature neutrophils. This binding initiates a complex cascade of intracellular signaling pathways (e.g., JAK/STAT pathway) that primarily stimulate the proliferation, differentiation, and functional commitment of granulocytic progenitor cells within the bone marrow. As a result, lenograstim significantly enhances the production, maturation, and subsequent release of neutrophils from the bone marrow into the peripheral circulation, thereby elevating neutrophil counts. Furthermore, it enhances the functional activity of mature neutrophils, improving their phagocytic activity, chemotaxis, and oxidative burst capacity, contributing to improved host defense against bacterial and fungal infections.
Commercial Brands (Alternatives)
No other brands found for this formula.